Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Analytical Tool - Apoptosis in Oncology -' returned 70 results - Page 1 of 4   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Analytical Tool - Apoptosis in Oncology   Bioseeker, Feb 2012 Analytical Tool - Apoptosis in Oncology "Analytical Tool - Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug Triple Analysis: Colorectal Cancer, Apoptosis and Angiogenesis   Bioseeker, Jan 2012, Pages: 4377 is based on the following publication: A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part Triple Analysis: Colorectal Cancer, Apoptosis and Peptides   Bioseeker, Dec 2011, Pages: 3579 II: Apoptosis The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased Triple Analysis: Leukemia, Apoptosis and Angiogenesis   Bioseeker, Jan 2012, Pages: 4468 on the following publication: A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part comprises defined and up Triple Analysis: Leukemia, Apoptosis and Peptides   Bioseeker, Dec 2011, Pages: 3670 of leukemia. This part is based on the following publication: A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug Triple Analysis: Lung Cancer, Apoptosis and Angiogenesis   Bioseeker, Jan 2012, Pages: 4644 is based on the following publication: Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market Part II: Apoptosis The apoptotic cancer drug report part comprises defined Triple Analysis: Lung Cancer, Apoptosis and Peptides   Bioseeker, Dec 2011, Pages: 3846 and and three subindications of lung cancer. This part is based on the following publication: Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market Part II: Apoptosis Triple Analysis: Lymphoma, Apoptosis and Angiogenesis   Bioseeker, Jan 2012, Pages: 4275 on the following publication: A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part comprises defined and up Triple Analysis: Lymphoma, Apoptosis and Peptides   Bioseeker, Dec 2011, Pages: 3477 of lymphoma. This part is based on the following publication: A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug Triple Analysis: Melanoma, Apoptosis and Angiogenesis   Bioseeker, Jan 2012, Pages: 4098 Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part comprises defined and up to date development strategies Triple Analysis: Melanoma, Apoptosis and Peptides   Bioseeker, Dec 2011, Pages: 3300 on the following publication: A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part comprises defined and up Triple Analysis: Prostate Cancer, Apoptosis and Angiogenesis   Bioseeker, Jan 2012, Pages: 4159 on the following publication: A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part comprises defined Triple Analysis: Prostate Cancer, Apoptosis and Peptides   Bioseeker, Dec 2011, Pages: 3361 in prostate cancer. This part is based on the following publication: A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market Part II: Apoptosis Triple Analysis: Apoptosis, Angiogenesis and Cancer Vaccines   Bioseeker, Jan 2012, Pages: 3980 : Apoptosis The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed Triple Analysis: Apoptosis, Cancer Vaccines and Peptides   Bioseeker, Dec 2011, Pages: 3182 in this report: Part I: Apoptosis The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Triple Analysis: Colorectal Cancer, Apoptosis and Antibodies   Bioseeker, Dec 2011, Pages: 4617 II: Apoptosis The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased Triple Analysis: Leukemia, Apoptosis and Antibodies   Bioseeker, Dec 2011, Pages: 4708 subindications of leukemia. This part is based on the following publication: A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic Triple Analysis: Lung Cancer, Apoptosis and Antibodies   Bioseeker, Dec 2011, Pages: 4884 and and three subindications of lung cancer. This part is based on the following publication: Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market Part II: Apoptosis Triple Analysis: Lymphoma, Apoptosis and Antibodies   Bioseeker, Dec 2011, Pages: 4515 subindications of lymphoma. This part is based on the following publication: A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic Triple Analysis: Melanoma, Apoptosis and Antibodies   Bioseeker, Dec 2011, Pages: 4338 . This part is based on the following publication: A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market Part II: Apoptosis The apoptotic cancer drug report part Results:  First -   Prev -   1 -   2 -   3 -   4 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets2    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network